- Home
- GDTC vs NRXP Comparison
GDTC vs NRXP Comparison
Compare GDTC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- NRXP
- Stock Information
- Founded
- GDTC 2018
- NRXP 2015
- Country
- GDTC Singapore
- NRXP United States
- Employees
- GDTC N/A
- NRXP N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- NRXP Health Care
- Exchange
- GDTC Nasdaq
- NRXP Nasdaq
- Market Cap
- GDTC 29.4M
- NRXP 34.7M
- IPO Year
- GDTC 2023
- NRXP N/A
- Fundamental
- Price
- GDTC $2.23
- NRXP $2.01
- Analyst Decision
- GDTC Buy
- NRXP Strong Buy
- Analyst Count
- GDTC 1
- NRXP 4
- Target Price
- GDTC $5.00
- NRXP $28.25
- AVG Volume (30 Days)
- GDTC 15.9K
- NRXP 185.3K
- Earning Date
- GDTC 01-01-0001
- NRXP 05-13-2025
- Dividend Yield
- GDTC N/A
- NRXP N/A
- EPS Growth
- GDTC N/A
- NRXP N/A
- EPS
- GDTC N/A
- NRXP N/A
- Revenue
- GDTC $330,254.00
- NRXP N/A
- Revenue This Year
- GDTC $14.71
- NRXP N/A
- Revenue Next Year
- GDTC N/A
- NRXP N/A
- P/E Ratio
- GDTC N/A
- NRXP N/A
- Revenue Growth
- GDTC N/A
- NRXP N/A
- 52 Week Low
- GDTC $1.20
- NRXP $1.10
- 52 Week High
- GDTC $4.05
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- GDTC 34.89
- NRXP 42.26
- Support Level
- GDTC $1.98
- NRXP $1.95
- Resistance Level
- GDTC $2.56
- NRXP $2.12
- Average True Range (ATR)
- GDTC 0.18
- NRXP 0.18
- MACD
- GDTC -0.04
- NRXP 0.01
- Stochastic Oscillator
- GDTC 31.25
- NRXP 23.08
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.